Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.54 |
| ▸ | CCKAR | P32238 | 7/20 | 0.53 |
| ▸ | CCKBR | P32239 | 7/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274819 | 0.85 | OPRD1 (0.51) | OPRD1OPRM1OPRK1GLP1R | |
| SCHEMBL30426861 | 0.81 | OPRD1 (0.56) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30646307 | 0.81 | OPRD1 (0.52) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29723185 | 0.81 | OPRD1 (0.53) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31257053 | 0.81 | OPRD1 (0.53) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30974312 | 0.80 | OPRD1 (0.63) | OPRD1OPRM1OPRK1GLP1R | |
| SCHEMBL22005320 | 0.80 | OPRD1 (0.68) | OPRD1CCKARCCKBROPRM1OPRK1 | |
| SCHEMBL30510653 | 0.80 | GLP1R (0.51) | OPRD1OPRM1OPRK1GLP1R | |
| SCHEMBL29705076 | 0.80 | OPRD1 (0.45) | OPRD1OPRM1OPRK1GLP1R | |
| SCHEMBL7972955 | 0.80 | NPY4R (0.51) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | H LEE MOFFITT CANCER CT & RES (US) | 2025-04-24 | — | — | US | disclosed |
| CN-117836011-A | Methods and materials for combining biological agents with various chelators | 梅约医学教育与研究基金会 | 2024-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | MC1R, MC3R, MC5R | OPRD1 1060/4885CCKAR 24/4885CCKBR 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.